In vitro antitumor effect of AZD4547 in ovarian cancer cell lines.

被引：0
|
作者：
Seo, Ji Hae [1 ]
Lee, Seungmee [2 ]
Cho, Chi-Heum [2 ]
Shin, So-Jin [2 ]
机构：
[1] Keimyung Univ, Sch Med, Daegu, South Korea
[2] Keimyung Univ, Dongsan Hosp, Daegu, South Korea
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1012
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The FGFR Family Inhibitor AZD4547 Exerts an Antitumor Effect in Ovarian Cancer Cells
    Na, Yu Ran
    Kim, Jin Young
    Song, Chang Ho
    Kim, Mikyung
    Do, Yen Thi
    Vo, Tam Thuy Lu
    Choi, Eunsom
    Ha, Eunyoung
    Seo, Ji Hae
    Shin, So-Jin
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (19)
  • [2] Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells
    Kwak, Yeonui
    Cho, Hanna
    Hur, Wooyoung
    Sim, Taebo
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (10) : 2292 - 2302
  • [3] In Vitro and in Vivo Efficacy of AZD9291 Is Enhanced by Combination with AZD4547 in EGFR Mutant Lung Cancer Cells
    Chan, Daniel C.
    Hinz, Trista K.
    Marek, Lindsay A.
    Zhang, Zhiyong
    Nguyen, Teresa T.
    Bunn, Paul A., Jr.
    Heasley, Lynn
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S580 - S581
  • [4] Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model
    Jang, Jiryeon
    Kim, Hee Kyung
    Bang, Heejin
    Kim, Seung Tae
    Kim, Sun Young
    Park, Se Hoon
    Lim, Ho Yeong
    Kang, Won Ki
    Lee, Jeeyun
    Kim, Kyoung-Mee
    TRANSLATIONAL ONCOLOGY, 2017, 10 (04): : 469 - 475
  • [5] AZD4547 and the Alleviation of Hepatoma Cell Sorafenib Resistance via the Promotion of Autophagy
    Feng, Yun
    Zhang, Dan
    He, Gaixia
    Liu, Yaping
    Zhao, Yan
    Ren, Xiaoyang
    Sun, Huanhuan
    Lu, Guifang
    Zhang, Zhiyong
    Ren, Li
    Yin, Yan
    Li, Hongxia
    He, Shuixiang
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2022, 22 (18) : 3107 - 3113
  • [6] AZD4547 and AZD5363 synergistically inhibit prostate cancer progression by modulating MAPK and AKT activation
    Feng, Shu
    Ittnnann, Michael
    CANCER RESEARCH, 2016, 76
  • [7] Evaluation of the pan-FGFR inhibitor AZD4547 with radiation in non-small cell lung cancer
    Miller, Margot
    Fisher, Michael
    Senthilkumar, Gopika
    Kaushik, Saakshi
    Able, Lindsey
    Brennan, Sean
    Iyer, Gopal
    Kimple, Randall
    Baschnagel, Andrew M.
    CANCER RESEARCH, 2019, 79 (13)
  • [8] THERAPEUTIC POTENTIAL OF THE FGFR TYROSINE KINASE INHIBITOR, AZD4547 IN SQUAMOUS NON-SMALL CELL LUNG CANCER
    Gavine, Paul
    Smith, Neil
    Baker, Dawn
    Rooney, Claire
    Guichard, Sylvie
    Denz, Christopher
    Dougherty, Brian
    Zhang, Jingchuan
    Zhang, Lin
    Su, Xinying
    Li, Ming
    Fan, Shuqiong
    Yin, Xiaolu
    Xu, Yanping
    Liu, Kunji
    Dong, Zhenwei
    Zhu, Guanshan
    Ferry, David
    Stockman, Paul
    Brooks, Nigel
    Kilgour, Elaine
    Smith, Paul D.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S777 - S777
  • [9] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
    Coombes, R. C.
    Badman, P. D.
    Lozano-Kuehne, J. P.
    Liu, X.
    Macpherson, I. R.
    Zubairi, I
    Baird, R. D.
    Rosenfeld, N.
    Garcia-Corbacho, J.
    Cresti, N.
    Plummer, R.
    Armstrong, A.
    Allerton, R.
    Landers, D.
    Nicholas, H.
    McLellan, L.
    Lim, A.
    Mouliere, F.
    Pardo, O. E.
    Seckl, M. J.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [10] Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
    R. C. Coombes
    P. D. Badman
    J. P. Lozano-Kuehne
    X. Liu
    I. R. Macpherson
    I. Zubairi
    R. D. Baird
    N. Rosenfeld
    J. Garcia-Corbacho
    N. Cresti
    R. Plummer
    A. Armstrong
    R. Allerton
    D. Landers
    H. Nicholas
    L. McLellan
    A. Lim
    F. Mouliere
    O. E. Pardo
    V. Ferguson
    M. J. Seckl
    Nature Communications, 13
12345